A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
NCT07233018 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2025-11-18
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
Interventions
- DRUG
-
CT0991 CAR-T cells infusicn
CAR-T cells# chimeric antigen receptor T cells#
Sponsors & Collaborators
-
MEI HENG
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-18
- Primary Completion
- 2026-06-30
- Completion
- 2027-05-30
Countries
- China
Study Locations
More Related Trials
-
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04265963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.
NCT04014881 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
NCT06730256 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
NCT06718270 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07043218 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Donor-derived CAR-T Cells in the Treatment of AML Patients
NCT04766840 ·Status: UNKNOWN ·Phase: PHASE1
-
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）
NCT03556982 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
NCT04532281 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML
NCT05467202 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of CT071 Injection in RRMM or PPCL
NCT05838131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies
NCT04689204 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
NCT06762132 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05309213 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04792593 ·Status: UNKNOWN ·Phase: NA
-
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
NCT07234110 ·Status: RECRUITING ·Phase: NA
-
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
NCT06420063 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05722171 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
NCT03544021 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
NCT05467254 ·Status: UNKNOWN ·Phase: PHASE1
-
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT05488132 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
NCT07201727 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1